A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

NCT03538028 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Cervical Cancer
Microsatellite Instability (MSI)-High Endometrial Cancer
Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])
Esophageal Cancer
Hepatocellular Carcinoma
Melanoma (Uveal Melanoma Excluded)
Merkel Cell Carcinoma
Mesothelioma
MSI-high Colorectal Cancer
Non-small Cell Lung Cancer (NSCLC)
Ovarian Cancer
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Small Cell Lung Cancer (SCLC)
Renal Cell Carcinoma (RCC)
Triple-negative Breast Cancer
Urothelial Carcinoma
Diffuse Large B-cell Lymphoma

Interventions

BIOLOGICAL: INCAGN02385

Sponsor

Incyte Biosciences International Sàrl